The V804M mutation in RET confers resistance to<unk>  anti-RET activity. In people with moderate and severe hepatic impairment, no dosage for<unk>  has been recommended, as its safety and efficacy has not been established yet.<unk>  is contraindicated in people with congenital long QT syndrome.
Vandetanib
Selepressin
Masitinib
Vatalanib
Alectinib
Pegaptanib
Enasidenib
Tivozanib